Intrinsiqq
Exicure, Inc. logo

Exicure, Inc. Financials

XCUR

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 11 available years
Income Statement
TTM
DEC 2025
3:1 split
DEC 2024
DEC 2023
~1.7:1 split
DEC 2022
~1.6:1 split
DEC 2021
Revenues
Revenue$0$0$1$0$29-$0
General & Administrative$4$7$5$12$11$13
Research & Development$1$3$0$1$20$49
Total Operating Expenses$6$4$13$15$31$62
Operating Income-$6-$4-$12-$15-$2-$63
Non-Operating
Net Interest Expense$0$0-$0$0-$1-$2
Other Non-Operating Income (Expense)-$0-$1$3-$2$0-$0
EBT (Earnings Before Tax)-$6-$6-$10-$17-$2-$64
Income Tax Expense-$1-$1$0$0$0$0
Net Income
Net Income-$5-$5-$10-$17-$3-$64
Per Share Data
Revenue Per Share$0.00$0.00$0.24$0.00$31.20-$0.82
EPS (Basic)-$0.85-$0.79-$4.75-$10.55-$2.80-$108.50
EPS (Diluted)-$0.85-$0.79-$4.75-$10.55-$2.80-$108.50
Weighted Avg Shares (Basic)6.5M6.3M2.0M8.0M4.6M88.6M
Weighted Avg Shares (Diluted)6.5M6.3M2.0M8.0M4.6M88.6M
Shares Outstanding6.5M6.3M2.0M1.6M923,894.2590,782.213

Exicure (XCUR) financials: revenue, profit and margins

Exicure (XCUR) generated about $0.00 in revenue and -$5 million in net income over the trailing twelve months, growing at roughly -44.8% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Exicure's (XCUR) revenue?+

Exicure generated about $0.00 in revenue over the trailing twelve months. Revenue has grown at roughly -44.8% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Exicure profitable?+

Exicure reported about -$5 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Exicure growing?+

Exicure's revenue has compounded at roughly -44.8% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside XCUR's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 18 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 20 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with XCUR

CompareIntrinsic value
ISCOInternational Stem Cell Corporation
$0.17+6.25%29
BIXTBioxytran Inc.
$0.02-13.28%25
OWPCOne World Products Inc.
$0.00+0.00%46
GCANThe Greater Cannabis Company, Inc.
$0.75-24.09%20
EMMAEmmaus Life Sciences, Inc.
$0.04+52.17%21
CPHIChina Pharma Holdings Inc.
$0.44-12.32%25
ENTAEnanta Pharmaceuticals Inc.
$7.62-4.51%25
BDPTBioadaptives Inc.
$0.00-4.00%25

Spot a number that looks wrong? Check it in XCUR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing XCUR

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.